List prices for Medicare negotiation-eligible medicines targeted by Build Back Better drug pricing provisions estimated to be reduced by over 40% on average.

GPI attended and presented research at ISPOR, held at the Gaylord Resort & Convention Center, Washington D.C, United States on 15-18 May 2022. GPI presented three research posters, including ‘List prices for Medicare negotiation-eligible medicines targeted by Build Back Better drug pricing provisions estimated to be reduced by over 40% on average‘. The research looks into detail at the Build Back Better social spending bill and the impact of drug pricing within the US, for Medicare negotiation-eligible list prices.

Background & Objective

The Build Back Better social spending bill recently passed in the House of Representatives on 19 November includes unprecedented drug pricing controls for drugs covered under Medicare, including empowering the program to negotiate prices for up to 10 highest-cost Medicare drugs annually, starting from 2025 for Part D and 2027 for Part B, and establishing inflation rebates that could notably temper the rate of drug price increases over time. This research analysis aims to identify the drugs likely to be targeted by the Medicare negotiation provision of the proposed legislation.

Research Details

Conference: ISPOR

Focus Topics: Build Back Better, Medicare Drugs, US Drug Pricing, Market Access

Resources: GPI pulse™ Data Analytics Platform, GPI consulting, Price & Market Access Specialists

List prices for Medicare negotiation-eligible medicines targeted by Build Back Better

Find out more about GPI

---

This research, and all of our research, utilise data from our analytics platform, GPI pulse™.